Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation - Wikidata - wikimedia - TriplyDB

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation

http://www.wikidata.org/entity/Q36983469

about

Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies Effect of Fe(3)O(4)-magnetic nanoparticles on acute exercise enhanced KCNQ(1) expression in mouse cardiac muscle Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor.Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study.Development of copper based drugs, radiopharmaceuticals and medical materials.Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents.Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer A neuropeptide speeds circadian entrainment by reducing intercellular synchrony.Genomic biomarkers for molecular imaging: predicting the future Review: Receptor Targeted Nuclear Imaging of Breast Cancer.Radiometallated peptides for molecular imaging and targeted therapy.Rationale for the use of radiolabelled peptides in diagnosis and therapy.Molecular imaging probes derived from natural peptides.VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.VPAC1 Targeted 64Cu-TP3805 kit preparation and its evaluation.VPAC1 receptors for imaging breast cancer: a feasibility study.VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235.

P2860

Q33624771-D7CD9F93-E217-4461-925D-929E7D23327D Q33738469-92B4D536-ED1E-4815-BF0D-F7A41D33802D Q34474669-E75C3FEC-6BA7-440E-A611-71CCDDD4959E Q36246097-874423D2-9AD8-4C50-93B1-D54B97B5A3D1 Q36394415-D5114878-5F20-499B-8FAF-611B262F47F6 Q36579924-7D567DEC-1A5E-4855-B0AC-1EF905391A9E Q36834005-D58206A9-AEE6-40D2-A842-EE0AC4525F77 Q37319726-9D0431D2-4C10-44CD-A224-DCAADF25EE26 Q37508283-111BB3B5-4D80-4AAF-8D66-4EDACA8CD022 Q37690662-17F92B64-CE47-4820-B2F5-486E42FCFBF7 Q37847064-8096DDF1-F4BC-4176-99B3-F1606D0A07A0 Q37990410-55810404-207B-4E9C-9B51-D0525F5267F8 Q38748846-A335C939-CCCB-4D63-A9B3-E0535660448A Q38948710-182B3DFD-6677-49B2-9297-C34865446DD3 Q40036038-967B0CB7-9E84-42B6-B028-2EB236A3C67F Q40475702-B4A654F5-A6DA-4801-9F24-3B4883B63B59 Q40991225-BC1A8B65-7C27-4192-973F-E30A298C6CAB Q42573452-AC2697E9-6DBF-4A5C-8794-142C075C1FA1

P2860

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation

http://www.wikidata.org/entity/Q36983469

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Vasoactive intestinal peptide ...... r: In vitro/in vivo evaluation

@en

type

label

Vasoactive intestinal peptide ...... r: In vitro/in vivo evaluation

@en

prefLabel

Vasoactive intestinal peptide ...... r: In vitro/in vivo evaluation

@en

P1433

Q36983469-89C45385-ACD7-40ED-88FD-721B656D5E28

P1476

Q36983469-7F5B371C-C664-47BE-8DB3-CE02BC773C62

P2093

Q36983469-089AA60F-A503-4853-BDA9-092459AEE2ED

Q36983469-1D48539B-9C29-41E2-9205-51C4241F74A7

Q36983469-2D6E5141-4B3E-41A2-9AEF-C913913F00D1

Q36983469-4B24314A-514E-45B1-8E3A-766595168F59

Q36983469-7358EF87-8F7B-4AFF-A29D-FA07DFC19398

Q36983469-8CE28941-2C32-42EC-A68B-DDD0F657755C

Q36983469-E5C4832B-B859-4569-B301-B26FA604BB83

Q36983469-FE31A1C8-A2B8-4A0E-AA4D-718EA75FFBE9

P2860

Q36983469-06C71D70-CC9E-43E1-BE74-D63C7A2387BC

Q36983469-1D9A5B96-62E6-403E-BCDB-01CD12FDBCE9

Q36983469-25B93FA9-9FF0-4BE8-AA5A-864A9DFF7E70

Q36983469-25D03A46-A34C-411A-A138-B14801A382CD

Q36983469-28114F94-9956-4EF6-AFC1-9EAEB6C5C2F3

Q36983469-34E26E10-FBE6-4505-B7B5-748C0113C63E

Q36983469-3B1E1FE1-59EE-4277-8701-BFFBEDC9DA2F

Q36983469-4523CBF0-827A-48D1-A6EA-160E4B73ED5F

Q36983469-470E3D95-E892-477E-998E-97F00964D66C

Q36983469-48A3B168-7014-41D8-9F6B-9F1F54B474E7

P304

Q36983469-7212C9E3-C8C0-4F89-A7A8-CB3B0FA393EA

P31

Q36983469-C9B4BA99-95F3-4BA7-BB48-199FC7336842

P356

Q36983469-D103F875-9701-4B8C-93F6-2AD462E3CB14

P433

Q36983469-B17AC25C-1D66-42C7-BA3A-57E61A073A16

P478

Q36983469-8E2D4FA0-3704-4F0D-BDF0-136C172E1A65

P50

Q36983469-E3C28282-54BD-4BC7-A016-DB7B57A635B0

P577

Q36983469-6D9BEAEE-DB98-4598-9640-2CF17144797E

P5875

Q36983469-0CF3CB25-8F0D-4AD7-95AC-432D892586CD

P698

Q36983469-C0BCA7A8-E59D-4D7C-8365-947E405E994E

P932

Q36983469-0850D50E-AF6F-466A-A4F4-CF1A197D6DA4

P356

J.REGPEP.2007.06.008

P1433

Regulatory Peptides

P1476

Vasoactive intestinal peptide ...... r: In vitro/in vivo evaluation

@en

P2093

Chirag A Patel

http://www.w3.org/2001/XMLSchema#string

Christopher A Cardi

http://www.w3.org/2001/XMLSchema#string

Eric Wickstrom

http://www.w3.org/2001/XMLSchema#string

Gregory Cesarone

http://www.w3.org/2001/XMLSchema#string

Kaijun Zhang

http://www.w3.org/2001/XMLSchema#string

Mathew L Thakur

http://www.w3.org/2001/XMLSchema#string

Mohan R Aruva

http://www.w3.org/2001/XMLSchema#string

Nylla Shanthly

http://www.w3.org/2001/XMLSchema#string

P2860

Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin

Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP

VPAC receptors for VIP and PACAP

PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells.

In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver.

Nuclear medicine advances in breast cancer imaging.

Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.

Breast MR imaging in the diagnostic setting.

Emerging technologies in breast cancer detection.

P304

91-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.REGPEP.2007.06.008

http://www.w3.org/2001/XMLSchema#string

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6112376

http://www.w3.org/2001/XMLSchema#string

P698

17727979

http://www.w3.org/2001/XMLSchema#string

P932

2587158

http://www.w3.org/2001/XMLSchema#string